EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Synergistic combination of perphenazine and temozolomide suppresses patient-derived glioblastoma tumorspheres

Jun Pyo Hong, Ran Joo Choi, Jin-Kyoung Shim, Kibyeong Kim, Ryong Nam Kim, HyeJoung Cho, Seo Jin Kim, Sohyun Kim, Nam Hwa Kim, Hun Ho Park iD, Ju Hyung Moon, Eui Hyun Kim und 4 weitere

Neuro-Oncology · 07.03.2025 · 27 (3) · 654-667

DOI: 10.1093/neuonc/noae211 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuro-Oncology, online erschienen am 11.10.2024. Verfasst von Jun Pyo Hong und 15 weiteren Autor:innen. Beteiligte Einrichtung: Brain Tumor Translational Research Laboratory, Department of Biomedical Sciences, Yonsei University College of Medicine, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Temozolomide, Glioblastoma, Brain Neoplasms, Perphenazine. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Research Foundation of Korea, Korean Government, Pioneer Research Center Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Glioblastoma (GBM), a primary malignant brain tumor, has a poor prognosis, even with standard treatments such as radiotherapy and chemotherapy. In this study, we explored the anticancer effects of the synergistic combination of perphenazine (PER), a dopamine receptor D2/3 (DRD2/3) antagonist, and temozolomide (TMZ), a standard treatment for GBM, in patient-derived human GBM tumorspheres (TSs).

Methods

The biological effects of the combination of PER and TMZ in GBM TSs were assessed by measuring cell viability, ATP, stemness, invasiveness, and apoptosis. Changes in protein and mRNA expression were analyzed using western blotting and RNA sequencing. Co-administration of PER and TMZ was evaluated in vivo using a mouse orthotopic xenograft model.

Results

The Severance dataset showed that DRD2 and DRD3 expressions were higher in tumor tissues than in the tumor-free cortex of patients with GBM. DRD2/3 knockout by CRISPR/Cas9 in patient-derived human GBM TSs inhibited cell growth and ATP production. The combined treatment with PER and TMZ resulted in superior effects on cell viability and ATP assays compared to those in single treatment groups. Flow cytometry, western blotting, and RNA sequencing confirmed elevated apoptosis in GBM TSs following combination treatment. Additionally, the combination of PER and TMZ downregulated the expression of protein and mRNA associated with stemness and invasiveness. In vivo evaluation showed that combining PER and TMZ extended the survival period of the mouse orthotopic xenograft model.

Conclusions

The synergistic combination of PER and TMZ has potential as a novel combination treatment strategy for GBM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TemozolomideGlioblastomaBrain NeoplasmsPerphenazineAntineoplastic Combined Chemotherapy ProtocolsHumansAnimalsMiceXenograft Model Antitumor AssaysApoptosisCell ProliferationDrug SynergismReceptors, Dopamine D2Tumor Cells, CulturedMice, NudePrognosisMaleFemaleReceptors, Dopamine D3Antineoplastic Agents, Alkylating

Stichwörter der Autor:innen

DRD2/3glioblastomaperphenazinetemozolomidetumorsphere

Substanzen

TemozolomidePerphenazineReceptors, Dopamine D2Receptors, Dopamine D3Antineoplastic Agents, Alkylating

Autor:innen und Institutionen

  • Brain Tumor Translational Research Laboratory, Department of Biomedical Sciences, Yonsei University College of Medicine, Seoul, Republic of Korea.
  • Department of Neurosurgery, Brain Tumor Center, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.
  • Department of Physiology, Yonsei University College of Medicine, Seoul, Republic of Korea.
  • Department of Premedical, Yonsei University College of Medicine, Seoul, Republic of Korea.
  • Institute of Molecular and Cell Biology, A*STAR, Singapore, Singapore.
  • Cancer and Stem Cell Biology Program, Duke-NUS Medical School, Singapore, Singapore.

ORCID-Profile: Hun Ho Park, Seok-Gu Kang

Förderung

  • National Research Foundation of Korea
  • Korean Government
  • Pioneer Research Center Program
  • Ministry of Science
  • ICT & Future Planning
  • Yonsei University College of Medicine
  • Korea Health Technology R&D Project
  • Korea Health Industry Development Institute

Zitieren

APA

Hong, J. P., Choi, R. J., Shim, J. K., Kim, K., Kim, R. N., Cho, H., Kim, S. J., Kim, S., Kim, N. H., Park, H. H., Moon, J. H., Kim, E. H., Teo, W. Y., Chung, S., Chang, J. H., & Kang, S. G. (2025). Synergistic combination of perphenazine and temozolomide suppresses patient-derived glioblastoma tumorspheres. Neuro-Oncology, 27(3), 654-667. https://doi.org/10.1093/neuonc/noae211

Vancouver

Hong JP, Choi RJ, Shim JK, Kim K, Kim RN, Cho H, et al. Synergistic combination of perphenazine and temozolomide suppresses patient-derived glioblastoma tumorspheres. Neuro-Oncology. 2025;27(3):654-667. doi:10.1093/neuonc/noae211

BibTeX
@article{Hong2025,
  author = {Hong, Jun Pyo and Choi, Ran Joo and Shim, Jin-Kyoung and Kim, Kibyeong and Kim, Ryong Nam and Cho, HyeJoung and Kim, Seo Jin and Kim, Sohyun and Kim, Nam Hwa and Park, Hun Ho and Moon, Ju Hyung and Kim, Eui Hyun and Teo, Wan-Yee and Chung, Seungsoo and Chang, Jong Hee and Kang, Seok-Gu},
  title = {Synergistic combination of perphenazine and temozolomide suppresses patient-derived glioblastoma tumorspheres},
  journal = {Neuro-Oncology},
  year = {2025},
  volume = {27},
  number = {3},
  pages = {654--667},
  doi = {10.1093/neuonc/noae211}
}
Kostenlos starten →